The effect of Iranian capripoxvirus vaccine strains on neutralizing antibody titer in cattle

Iranian Journal of Veterinary Science and Technology

مقاله 11، دوره 12، شماره 2 - شماره پیاپی 23، اسفند 2020، صفحه 77-82   

نوع مقاله: Short communication

شناسه دیجیتال (DOI): 10.22067/veterinary.v12i2.84928

نویسندگان

Hamed Isapour¹؛ Mehdi Sakha^{* 2}؛ Hamid reza Varshovi³

¹Resident of large animal internal medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran.

²Department of Clinical Sciences, Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran.

³Department of Animal Viral Vaccines, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.

چکیده

Lumpy skin disease (LSD) virus, Goat-poxvirus (GPV), and Sheep-poxvirus (SPV) are members of genus capripoxvirus (CaPV) and have close genetic similarity. The use of CaPV-vaccine strains would be useful to protect the cattle against LSD. This study aimed to compare the neutralizing antibody titer of Iranian heterologous sheep pox and goat pox vaccines against LSD in cattle. A total of 100 calves was vaccinated with Gorgan-GPV and Ramyar-SPV vaccines on separate farms. Neutralizing antibody titer and side effects of vaccines were evaluated at days 14, 28, 45, 90, and 180 post-vaccination. The mean of rectal temperature in SPV was higher than GPV and persisted for up to 3 days. Also during the onset time of fever, ocular and nasal discharge were observed, whereas in the GPV and control group no clinical signs were observed. In each vaccinated group, the first detectable antibody titer was after 14 days and rose to peak at 28-45 days post-vaccination, then it decreased in the following days. Although, the mean of the neutralizing index (NI) titer between GPV and SPV was relatively similar and there was no statistically significant difference (p > 0.05) at all days of the experiment, but in GPV the titer appeared slightly higher than SPV and reached to protective level (NI ≥ 1.5) on day 45 post-vaccination. There was a high antibody titer (Log101.07) in the day 180 post-vaccination. The results showed that GPV vaccine because of the induction of the protective level of antibody titer, and persisting within  a long period for up to 180 day post-vaccination, has a good immunogenic response, so is considered a suitable vaccine to control LSD.

کلیدواژه‌ها

sheep pox virus؛ goat pox virus؛ capripox vaccine؛ Neutralizing antibody

مراجع

1.    OIE. Manual of Diagnostic tests and vaccines for terrestrial animals. paris: World Organization for Animal Health; 2004. p. 1-17.
2.    Murphy F, Gibbs E, Horzinek M, Studdert M. Veterinary Virology. 3rd. USA: Academic Press; 1999. p. 277-91.
3.    Carn VM. Control of capripoxvirus infections. Vaccine. 1993;11(13):1275-9.
4.    OIE. Lumpy skin diseas; Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. paris: World Organization for Animal Health; 2010. p. 1-13.
5.    Kitching RP. Vaccines for lumpy skin disease, sheep pox and goat pox. Dev Biol (Basel). 2003;114:161-7.
6.    Carn VM, Kitching RP. The clinical response of cattle experimentally infected with lumpy skin disease (Neethling) virus. Arch Virol. 1995;140(3):503-13.
7.    Gari G, Abie G, Gizaw D, Wubete A, Kidane M, Asgedom H, et al. Evaluation of the safety, immunogenicity and efficacy of three capripoxvirus vaccine strains against lumpy skin disease virus. Vaccine. 2015;33(28):3256-61.
8.    Kitching RP, Hammond JM, Taylor WP. A single vaccine for the control of capripox infection in sheep and goats. Res Vet Sci. 1987;42(1):53-60.
9.    Davies FG, Otema C. Relationships of capripox viruses found in Kenya with two Middle Eastern strains and some orthopox viruses. Res Vet Sci. 1981;31(2):253-5.
10.    Norian R, Ahangran NA, Varshovi H, Azadmehr A. Comparative efficacy of two heterologous capripox vaccines to control lumpy skin disease in cattle. Bulg J Vet Med. 2019;22(2).
11.    Varshovi H, Ghazanfari K, Aghaeipour K, Pourbakhsh S, Shoushtari A, Aghaebrahimian M. Capripoxvirus identification by PCR based on P32 gene. Arch Razi Inst. 2009;64(1):19-25.
12.    Tuppurainen ES, Oura CA. Review: lumpy skin disease: an emerging threat to Europe, the Middle East and Asia. Transbound Emerg Dis. 2012;59(1):40-8.
13.    Brenner J, Bellaiche M, Gross E, Elad D, Oved Z, Haimovitz M, et al. Appearance of skin lesions in cattle populations vaccinated against lumpy skin disease: statutory challenge. Vaccine. 2009;27(10):1500-3.
14.    OIE. Lumpy skin Disease; In Manual of standards chapter. World Organization for Animal Health; 2000. p. 200-17.
15.    Gari G, Bonnet P, Roger F, Waret-Szkuta A. Epidemiological aspects and financial impact of lumpy skin disease in Ethiopia. Prev Vet Med. 2011;102(4):274-83.
16.    Coetzer JAW. Lumpy skin disease; Infectious Diseases of Livestock. Oxford University Press; 2004.
17.    OIE. Manual of recommended diagnostic techniques and requirements for biological products. World Organization for Animal Health: Rue de Prony; 1992. p. 1-5.
18.    Diallo A, Viljoen GJ. Genus capripoxvirus.  Poxviruses: Springer; 2007. p. 167-81.
19.    Norian R, Afzal Ahangaran N, Azadmehr A. Evaluation of Humoral and Cell-mediated Immunity of Two Capripoxvirus Vaccine Strains against Lumpy Skin Disease Virus. Iran J Virol. 2016;10(4):1-11.
20.    Varshovi HR, Norian R, Azadmehr A, Ahangaran NA. Immune response characteristics of Capri pox virus vaccines following emergency vaccination of cattle against lumpy skin disease virus. Iran J Vet Sci Technol. 2018;9(2):33-40.
21.    Tilahun Z, Berecha B, Simenew K, Reta D. Towards Effective Vaccine Production: A Controlled Field Trial on the Immunological Response of Three Lumpy Skin Disease Vaccine Strains in Dairy Farms. Academic J Animal Dis. 2014;3(3):17-26.
22.    Kitching RPaH, J.M. . Poxvirus infection and immunity. In: P.J. RIMaD, editor. Encyclopaedia of Immunology 3. Academic press, London1992. p. 1261-4.
23.    Barman D, Chatterjee A, Guha C, Biswas U, Sarkar J, Roy TK, et al. Estimation of post-vaccination antibody titre against goat pox and determination of protective antibody titre. Small Rumin Res. 2010;93(2):76-8.
24.    Varshovi H, Norian R, Azadmehr A, Ahangaran N. Immune response characteristics of Capri pox virus vaccines following emergency vaccination of cattle against lumpy skin disease virus. Iran J Vet Sci Technol. 2017;9(2):33-40.
25.    Khafagy HA, Saad MA, Abdelwahab MG, Mustafa AM. Preparation and field evaluation of live attenuated sheep pox vaccine for protection of calves against lumpy skin disease. Benha Vet Med J. 2016;31(2):1-7.
26.    Mohamed G.Abdelwahab HAK, Abdelmoneim M. Moustafa, Mohamed A. Saad. Evaluation of Humoral and Cell-mediated Immunity of Lumpy Skin Disease Vaccine Prepared from Local strainin calves and Its Related to Maternal Immunity. J Ame Sci. 2016;21(10).
27.    Varshovi HR, Keyvanfar H, Aghaiypour K, Pourbakhsh SA, Shooshtari AH, Aghaebrahimian M. Capripoxvirus identification by PCR based on P32 gene Arch Razi Inst. 2009;64(No.1):19-25.
28.    Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27(3):493-7.
29.    Babiuk S, Bowden TR, Boyle DB, Wallace DB, Kitching RP. Capripoxviruses: An Emerging Worldwide Threat to Sheep, Goats and Cattle. Transbound Emerg Dis. 2008;55(7):263-72.
30.    Gari G, Biteau-Coroller F, LeGoff C, Caufour P, Roger F. Evaluation of indirect fluorescent antibody test (IFAT) for the diagnosis and screening of lumpy skin disease using Bayesian method. Vet Microbiol. 2008;129(3–4):269-80.